Online pharmacy company GoodRx Holdings (NASDAQ: GDRX) wasn’t the healthiest stock on the market Thursday. Its share price fell sharply, by almost 19% on the day, following the release of a new set of quarterly results. That steep decline wasn’t indicative of the broader equities space at all, as the S&P 500 index declined by a comparatively very modest 0.8%.
GoodRx’s third quarter saw the next-generation pharmacy earn revenue of just under $180 million, which unfortunately for it was notably below the analyst consensus of more than $188 million. It was also lower than the third-quarter 2022 figure of a bit over $187 million.
The dynamic was similar for adjusted non-GAAP (generally accepted accounting principles) net income; this slid to $25.5 million ($0.06 per share) from the year-ago profit of $29.9 million. Despite the drop, the result was in line with prognosticator projections.
The top-line slide was due in large part to a $10 million contract termination with a client GoodRx was forced to book as a reduction of revenue. Even stripping that out of the equation, though, leaves the company with only thin (1%) year-over-year growth in that line item.
GoodRx also proffered guidance for both its current (fourth) quarter and for full-year 2023. For the latter period, it’s anticipating revenue of $742 million to $748 million; however, that’s some distance underneath the collective analyst expectation of almost $755 million. The 2022 figure, meanwhile, was well higher at $767 million.
As for profitability, the company is forecasting adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in the high 20% range.
10 stocks we like better than GoodRx
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and GoodRx wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of November 6, 2023
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends GoodRx. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
